Join us in this insightful webinar as we delve into the dynamic reset seen within the biotech market, exploring the renewed optimism and trends impacting biotech companies and the strategic path to drug development.

This discussion illuminates the industry’s transition from adapting in uncertainty to growth within a vibrant era of innovation, with a focus on optimizing R&D spend to quickly deliver robust scientific evidence. Our experts will guide you through this compelling journey where scientific ambition intertwines with the ever-evolving landscape of clinical research and the importance of leveraging strategic partnerships to achieve remarkable outcomes.

• Explore regulatory challenges and opportunities with Project Optimus, diversity plans and data privacy.
• Gain insights on strategic drug development and how to successfully steer scientific endeavors through uncertain times.
• Understand the importance of innovative trial designs and master protocols in accelerating R&D processes and reducing development timelines.
• Discover how Generative AI is revolutionizing clinical trial conduct and how to navigate the inherent risks to optimize your clinical trial.

We look forward to your participation.

Speakers:

Meg Hooton
President
IQVIA Biotech

Murray Aitken
Executive Director
IQVIA Institute for Human Data Science

Keith McDonald
Head of Drug Development Strategy, Regulatory Affairs & Drug Development Solutions
IQVIA